---
title: "J&J Says New Model-Based Analysis Further Supports The Potential Of Tecvayli Plus Darzalex Faspro"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299912829.md"
datetime: "2026-09-23T14:34:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299912829.md)
  - [en](https://longbridge.com/en/news/299912829.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299912829.md)
generator: "portal-rs"
---

# J&J Says New Model-Based Analysis Further Supports The Potential Of Tecvayli Plus Darzalex Faspro

Sept 23 (Reuters) - Johnson & Johnson (JNJ.N) :

-   NEW MODEL-BASED ANALYSIS FURTHER SUPPORTS THE POTENTIAL OF TECVAYLI® (TECLISTAMAB-CQYV) PLUS DARZALEX FASPRO® (DARATUMUMAB AND HYALURONIDASE-FIHJ) TO REDEFINE LONG-TERM SURVIVAL EXPECTATIONS IN EARLY LINE RELAPSED/REFRACTORY MULTIPLE MYELOMA
-   J&J - ANALYSIS ESTIMATES 87% OF TECVAYLI PLUS DARZALEX FASPRO PATIENTS HAVE COMPARABLE MORTALITY RISK TO GENERAL POPULATION
-   J&J - TECVAYLI PLUS DARZALEX FASPRO REDUCES MULTIPLE MYELOMA PROGRESSION RISK BY 90% VERSUS STANDARD OF CARE

Source text:

Further company coverage: (JNJ.N)

### Related Stocks

- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)

## Related News & Research

- [Trajan Wealth LLC Has $10.13 Million Stake in Johnson & Johnson $JNJ](https://longbridge.com/en/news/298127700.md)
- [Johnson & Johnson $JNJ Position Reduced by Oppenheimer Asset Management Inc.](https://longbridge.com/en/news/296697035.md)
- [Polymarket Odds: Will MU, FDS Beat Earnings Tomorrow?](https://longbridge.com/en/news/300470494.md)
- [What's Going On With Oracle Stock Tuesday?](https://longbridge.com/en/news/300437295.md)
- [Stock of the Day: Why did MongoDB Reverse?](https://longbridge.com/en/news/300461555.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**